Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile

By Reuters News

Sept 28 (Reuters) - Kodiak Sciences Inc. KOD.O:

  • ZENKUDA AND TABIRAFUSP-TED MEET PRIMARY ENDPOINTS IN PIVOTAL DAYBREAK TRIAL IN WAMD, WITH ZENKUDA DEMONSTRATING A POTENTIAL NEW STANDARD-OF-CARE PROFILE WITH STRONG IMMEDIACY AND SUSTAINED CLINICAL EFFECT WITH MAJORITY OF PATIENTS ON 24-WEEK DOSING INTERVAL USING STRICT TREAT-TO-DRYNESS REAL WORLD RETREATMENT CRITERIA.

  • KODIAK SCIENCES - ZENKUDA BLA PLANNED FOR Q4 2026 TO INCLUDE FIVE POSITIVE PHASE 3 STUDIES

  • KODIAK SCIENCES INC. - ZENKUDA AND TABIRAFUSP-TED DEMONSTRATED SAFETY CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AFLIBERCEPT

Further company coverage: KOD.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.